We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pulse Sequence Development on 3T Magnetic Resonance Imaging/Spectroscopy

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00309504
First Posted: April 3, 2006
Last Update Posted: February 26, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Cross Cancer Institute
Information provided by (Responsible Party):
AHS Cancer Control Alberta
March 31, 2006
April 3, 2006
February 26, 2016
March 2006
February 2012   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00309504 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Pulse Sequence Development on 3T Magnetic Resonance Imaging/Spectroscopy
Pulse Sequence Development on 3T Magnetic Resonance Imaging/Spectroscopy
The purpose of this study is to find ways to improve the appearance of tumours or markers that indicate the presence of tumours in Magnetic Resonance Imaging (MRI). Although based on the same technology, there are many ways to obtain images using MRI. The type of image that will be produced by the scanner depends on the instructions sent to the machine. These instructions tell different components of the machine when to turn on and off and all together are called a pulse sequence. These pulse sequences can get quite lengthy and intricate and small changes in them can produce considerable changes in the resulting image. the aim of this protocol is to alter existing pulse sequences to improve image appearance. This protocol will involve only healthy volunteers.
Not Provided
Observational
Observational Model: Case-Only
Not Provided
Not Provided
Non-Probability Sample
Local Healthy volunteers
Healthy
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
February 2012
February 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • healthy adult

Exclusion Criteria:

  • subject under 18 years of age
  • subject pregnant, or may be pregnant
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT00309504
22307
Yes
Not Provided
Not Provided
AHS Cancer Control Alberta
AHS Cancer Control Alberta
Cross Cancer Institute
Principal Investigator: Gino B. Fallone, PhD, FCCPH, DABR AHS Cancer Control Alberta
AHS Cancer Control Alberta
March 2012